Effect of Different Doses of Rosuvastatin on Blood NF-κB and sICAM-1 in Patients with Acute Coronary Syndrome

OBJECTIVE To investigate the effect of different doses of rosuvastatin with acute coronary syndrome (ACS) patients on blood nuclear factor of kappa-B(NF-κB) and soluble intercellular adhesion molecule-1(sICAM-1) expression. METHODS ACS patients were randomized into rosuvastatin 10 mg group and 20 mg group. And forty healthy people were set as control group. Levels of blood NF-κB and sICAM-1 and blood lipids were measured between before treatment and after treatment. RESULTS Levels of blood NF-κB and sICAM-1 in ACS patients were significantly higher than healthy control group(P<0.01). After 4 weeks’ treatment, levels of blood NF-κB and sICAM-1 were decreased in rosuvastatin 10 mg group and 20 mg group. After treatment, levels of blood NF-κB and sICAM-1 were decreased more significantly in rosuvastatin 20 mg group than 10 mg group(P<0.05). CONCLUSION Rosuvastatin can reduce the levels of blood NF-κB and sICAM-1 in ACS patients, and high dose group is more evident.